AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GS-9451 placebo
Description: placebo matching GS-9451 tablet QD
Study NCT01271790 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegasys®
Description: peginterferon alfa-2a (solution for injection) 180 µg/week
Study NCT01271790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Copegus®
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
Study NCT00949650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed IV given once every 3 weeks for up to 6 cycles
Study NCT00949650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: BIBW 2992 once daily until progression
Study NCT00949650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin IV given once every 3 weeks for up to 6 cycles
Study NCT03247998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Study NCT04191096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered as an IV infusion at 200 mg on Day 1 of each 21-day cycle for up to 35 cycles.
Study NCT04191096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
Study NCT04191096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide is administered orally as capsules/tablets at a dosage of 160 mg daily. Enzalutamide is administered continuously until criteria for discontinuation are met.
Study NCT04191096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
Study NCT04191096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen Deprivation Therapy (ADT)
Description: Stable regimen of ADT (LHRH agonist or antagonist) at a dose and frequency of administration that is consistent with the local product label.
Study NCT03864380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Color retinography
Description: Non mydriatic color retinography within 1 month before and within 1 hour after the marathon
Study NCT03864380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A
Description: Optical Coherence Tomography - Angiography within 1 month before and within 1 hour after the marathon
Study NCT03864380 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood pressure measurement
Description: Blood pressure measurement within 1 month before and within 1 hour after the marathon
Study NCT03835780 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: A observation of outcomes in usual practice
Study NCT04191096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo infusion solution is administered as an IV infusion on Day 1 of each 21-day cycle for up to 35 cycles.
Study NCT02965261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Fluoxetine Tablets
Study NCT02965261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warner Chilcott LLC Sarafem Tablets
Study NCT00597454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.~We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose.
Study NCT03503435 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group art therapy
Description: Participants will undergo 6 weeks of group art therapy in which they will learn tools to cope with a variety of cognitive, emotional and social aspects of life after TL.
Study NCT03850158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Indocyanine green is administered intra-venous after dilution with water in a peripheral vein at a dosage of 0.3mg/kg body weight as a bolus injection. The injection will take place during surgery. By using NIR fluorescence imaging ICG is made visible.
Study NCT01888276 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of word generation and of motivation
Description: Each subject will realize twice each test during 2 sessions with one hour in between :~During the session 1 :~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The test of Stroop that assesses selective attention~During the session 2:~* The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.~* The task of the casino (Iowa Gambling Test)~* The task of landing~* The test of Stroop
Study NCT01032213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
Study NCT01032213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Group S received the same volume of isotonic saline as same method.
Study NCT03336580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX004
Description: PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)
Study NCT03039985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crowns (Prettau®)
Description: Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
Study NCT03039985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lithium disilicate crowns (IPSe.max®)
Description: lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspirate
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT03701308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV
Study NCT03247998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conscious Sedation with Remifentanil
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Study NCT01686503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
Study NCT01686503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Description: Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
Study NCT01221298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450
Description: tablets
Study NCT03701308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT03701308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Given IV
Study NCT03701308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03701308 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study NCT03701308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uproleselan
Description: Given IV
Study NCT00790660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Oral
Study NCT00790660 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00191152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
Study NCT00191152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression
Study NCT00191152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m2, intravenous (IV), every 21 days until disease progression
Study NCT00191152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
Study NCT02331121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family First Aid Online Training
Description: Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
Study NCT02331121 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text-only Online Training
Description: Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
Study NCT04813874 — intervention group
Intervention type: DRUG
Intervention: Nitrous Oxide
Description: Nitrous Oxide Inhalational Agent
Study NCT04813874 — intervention group
Intervention type: PROCEDURE
Intervention: Neuraxial analgesia
Description: Epidural Labor Analgesia Placement
Study NCT02656342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Predicted to enhance stabilization of the effects of concentrated exposure treatment
Study NCT03277079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin + ezetimibe
Description: Combination of two drugs
Study NCT03277079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statin + ezetimibe + Nutraceuticals
Description: Combination of two grus plus nutraceuticals
Study NCT04099771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine infusion
Study NCT01997385 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: KAPD-C
Description: KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
Study NCT01997385 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: KAPD-A
Description: KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
Study NCT03053765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: training in IPT
Description: Follow-up training in IPT to determine which best enhances fidelity
Study NCT03053765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training in IPT
Description: Follow-up training in IPT to determine which best enhances fidelity
Study NCT04577352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study NCT04577352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatiquinone
Description: Vatiquinone will be administered per dose and schedule specified in the arm.
Study NCT04577352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered per schedule specified in the arm.
Study NCT02656342 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Predicted to have no enhancing effect
Study NCT03430570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tablet TRAC Emotion Regulation Intervention
Description: The intervention focuses on developmentally appropriate strategies for emotion regulation during difficult situations, particularly those related to risk, using 3 primary groups of strategies identified during qualitative work in Project TRAC (R34 MH078750): 1) getting away (physically or cognitively) from triggers for strong emotions, 2) releasing emotional energy in healthy ways (physically or verbally) or 3) changing cognitions and appraisals about emotional triggers. Using strategies effective in TRAC, teens will engage in games to practice and apply strategies to risk scenarios, as well as personalize content learned.
Study NCT01520714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead
Description: 1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
Study NCT01213771 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Preoperative preparation 2010
Description: Preoperative optimisation Supportive care LEAN in patient pathways
Study NCT04331379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Elevator
Description: A device aiming to elevate the clefted nostril extraorally and fixed on the forehead.
Study NCT04331379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taping Alone
Description: Horizontal tape alone.
Study NCT01774539 — intervention group
Intervention type: OTHER
Intervention: Diffusion MRI
Description: Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
Study NCT01392495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: 200 mg or 400 mg qd
Study NCT03299335 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: assay of CPK and anti-cN-1A antibodies
Study NCT04506710 — intervention group
Intervention type: BEHAVIORAL
Intervention: Audio recording of the counseling conversation
Description: The patient will have an audio-recorded counseling conversation. Audio recording will be carried out using a portable recorder ZOOM H2n. The audio recordings of the counseling conversations will be performed by the health workers selected to participate in the study.
Study NCT01221298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-072
Description: tablets
Study NCT01221298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: tablets
Study NCT01221298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: capsules
Study NCT04252807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm
Description: In addition to the routine care delivered by Lady Health Workers (LHWs), the participants in the intervention arm will receive common elements based integrated intervention. The providers of the intervention are lay health workers who will be trained in the intervention using an online course. The lay health worker will complete the online training course in a group, with interactive group activities and role plays. Lay health workers will be supported online and in-person by the trainers in monthly supervision meetings. The lay health workers will deliver intervention to distressed mothers in 15 monthly sessions. The intervention consists of three modules including 1) mothers' well-being, 2) infant nutrition,early stimulation and breastfeeding and 3) mother-infant interaction.
Study NCT02517138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Parabolic flight
Study NCT02517138 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Measurements of eye movements and perception
Study NCT01029197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT and exposure therapy for PTSD
Description: The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
Study NCT01029197 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
Study NCT02968875 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endurance Training
Description: 40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
Study NCT02968875 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic education meetings
Description: Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
Study NCT00984633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Org 9426)
Description: 0.6 mg/kg injection intubation dose
Study NCT00984633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide (Org 9426)
Description: 0.9 mg/kg injection intubation dose
Study NCT00984633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 0.5-2.0% intravenous maintenance anesthesia
Study NCT00984633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4-10 mg/kg/hr maintenance anesthesia
Study NCT04642066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Description: Full body CWI in open standing, except the head (same location, timing), frequency three times a week in the duration of 7-10 minutes. Swimming was permitted. Volunteers must not use neoprene aids (gloves, shoes), caps were allowed. Volunteers should be in the final phase submerged in water, above which there should only be the head and neck. The upper limbs were below the water surface. Non-neoprene footwear was permitted. Volunteers entered the water continuously without stopping. The time of stay in water was calculated from the first contact of the foot with water. On average, the whole body needed to be immersed in water within 30 seconds.
Study NCT04642066 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No cold water immersion
Description: People without cold water immersion
Study NCT00940511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coordinated care